OmniAb reported Q3 2026 revenue of $4.0M (up from $2.2M a year ago), net loss of $15.7M. The company raised full-year 2026 revenue guidance to $35M-$39M (from $32M-$36M) and cash outlook to $53M-$57M. It also announced a new ion channel collaboration with Eli Lilly worth up to $370M in milestones, expanded commercial launch of xPloration platform, and introduced OmniTides peptide discovery offering.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
